Categories: News

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Management to Host Conference Call

WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the third quarter of 2021 on Monday, November 8, 2021. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.

The live call may be accessed by dialing (877) 312-5845 (US and Canada) or (765) 507-2618 (international) and referring to conference ID number 3775536. The live webcast of the conference call can also be accessed online in the Investors and Media section of the Company’s website under “Events and Presentations” at ir.minervaneurosciences.com.

The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences

Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), in clinical development for negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. For more information, please visit our website.

For more information:
   
Investor inquiries: Media Inquiries:
Fred Ahlholm Helen Shik
CFO, Minerva Neurosciences  Principal, Shik Communications LLC
email email

Staff

Recent Posts

Tebra Launches AI Note Assist, Reducing Clinical Documentation Time by 50% for Independent Practices

New HIPAA-compliant AI technology integrated into Tebra’s EHR platform reduces documentation time by up to…

3 hours ago

New Multicenter Study Demonstrates SyMRI’s Potential to Transform Clinical Neuroimaging Workflows

LINKÖPING, Sweden, June 3, 2025 /PRNewswire/ -- SyntheticMR AB (publ) is proud to share the…

3 hours ago

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

Highly experienced biopharma executive Dr Cristina Csimma joins Asgard's Board of Directors, while esteemed immunologists…

3 hours ago

Sixth Global Pharma Company Selects LifeSphere NavaX for GenAI-Driven Case Processing

Top 25 Global Life Science Organization Adopts NavaX, Demonstrating Industry Confidence in Scalable, GenAI-Enabled Technologies…

3 hours ago

CareLineLive Secures Majority Investment from Technology Investment Firm Accel-KKR

LONDON and MENLO PARK, Calif., June 3, 2025 /PRNewswire/ -- CareLineLive, an all-in-one home care…

3 hours ago